ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Pharmaceuticals

COVID-19 vaccine developer CanSino reports $15m net loss

Chinese company earned no revenue as it has yet to commercialize any products

CanSino Biologics' "Ad5-nCoV" vaccine is undergoing late-stage clinical trial in Russia, Chinese state media reported.   © Reuters
CK TAN, Nikkei staff writer | China

SHANGHAI -- Chinese drugmaker CanSino Biologics is accelerating clinical trials for its coronavirus vaccine even as earnings remained in the red.

The Hong Kong and Shanghai-listed company on Friday reported a net loss of 102 million yuan ($15 million) on the back of zero revenue since it has yet to commercialize any products.

Read Next

Latest On Pharmaceuticals

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more

By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our Cookie Policy to learn how you can update your cookie settings.

Accept & Continue Close